Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aurinia Pharm Ord (NQ: AUPH )

7.110 -0.030 (-0.42%)
Streaming Delayed Price Updated: 9:46 AM EDT, Sep 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aurinia Pharm Ord

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Aurinia Pharmaceuticals Inc. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Aurinia Pharmaceuticals Inc. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
Aurinia Announces Year-Two Commitment to Patient Navigation Grant Program to Address Barriers for Individuals Living with Lupus and Lupus Nephritis
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Why Aurinia Pharmaceuticals Tumbled Despite Its 'Aggressive' 2022 Outlook
The company expects 150%-200% growth in its key product. But that wasn't enough. 
Via Investor's Business Daily
Shareholder Alert: Robbins LLP Informs Investors of Class Action Against Aurinia Pharmaceuticals Inc. (AUPH)
From Robbins LLP
Via Business Wire
EQUITY ALERT: Rosen Law Firm Encourages Aurinia Pharmaceuticals Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – AUPH
From The Rosen Law Firm, P.A.
Via Business Wire
AURINIA ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Aurinia Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
Earnings Scheduled For February 28, 2022
Companies Reporting Before The Bell • Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter. • Praxis Precision Medicine (... 
Via Benzinga
Expert Ratings For Aurinia Pharmaceuticals
Within the last quarter, Aurinia Pharmaceuticals (NASDAQ:AUPH) has observed... 
Via Benzinga
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) Investor Notice: Investigation over Possible Violations of Securities Laws
San Diego, CA -- (SBWIRE) -- 04/15/2022 -- An investigation was announced over potential securities laws violations by Aurinia Pharmaceuticals Inc. in connection with certain financial statements. 
Via SBWire
AUPH INVESTOR ALERT: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Aurinia Pharmaceuticals Inc. Investors with Losses to Inquire About Securities Class Action Investigation – AUPH
From Rosen Law Firm
Via Business Wire
Cramer Shares His Thoughts On PubMatic, Aurinia Pharmaceuticals And More
On CNBC’s "Mad Money Lightning Round," Jim Cramer said although Kulicke and Soffa Industries, Inc. 
Via Benzinga
Aurinia Pharmaceuticals Announces Presentations at the 2022 National Kidney Foundation Spring Clinical Meetings
From Aurinia Pharmaceuticals Inc.
Via Business Wire
INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Aurinia Pharmaceuticals Inc. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Aurinia Pharmaceuticals Inc. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
AUPH INVESTOR NOTICE: ROSEN, A TOP RANKED LAW FIRM, Encourages Aurinia Pharmaceuticals Inc. Investors with Losses to Inquire About Securities Class Action Investigation AUPH
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
What 4 Analyst Ratings Have To Say About Aurinia Pharmaceuticals
Over the past 3 months, 4 analysts have published their opinion on Aurinia Pharmaceuticals (NASDAQ:AUPH) stock. These analysts are typically employed by large Wall Street banks... 
Via Benzinga
10 Biggest Price Target Changes For Tuesday
Raymond James cut the price target on Ciena Corporation (NYSE: CIEN) from $80 to $75. Ciena shares fell 10.9% to close at $58.76 on Monday. Telsey Advisory Group cut Capri... 
Via Benzinga
67 Biggest Movers From Yesterday
Gainers Mullen Automotive, Inc. (NASDAQ: MULN) climbed 145.6% to close at $1.69 on Monday after the company reported progress on solid-state polymer battery pack... 
Via Benzinga
42 Stocks Moving In Monday's Mid-Day Session
Gainers Mullen Automotive, Inc. (NASDAQ: MULN) jumped 74.4% to $1.20 after the company reported progress on solid-state polymer battery pack development. Renewable Energy Group... 
Via Benzinga
Stocks Mixed as Investors Weigh Sanctions
U.S. markets have cut a great deal of this morning's losses, though the Dow Jones Industrial Average (DJI) is still down 
Via Talk Markets
Why Aurinia Pharmaceuticals Shares Are Falling Today
Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) is trading significantly lower Monday after the company reported declining fourth-quarter financial results on a year-over-year basis.... 
Via Benzinga
Mid-Morning Market Update: Markets Open Lower Amid Ongoing Russia-Ukraine Conflict
U.S. stocks opened on a downbeat note this morning, amid the ongoing Russia-Ukraine conflict, which has led to increased US sanctions on Russia. Following the market opening... 
Via Benzinga
Aurinia Reports Fourth Quarter and Full Year 2021 Financial Results and Company Updates
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Pharmaceuticals to Release Fourth Quarter and Year End 2021 Financial Results on February 28, 2021
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Pharmaceuticals to Present at the 11th Annual Leerink Global Healthcare Conference
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Pharmaceuticals to Present at Upcoming January Investor Conferences
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For December 10, 2021
Upgrades According to JP Morgan, the prior rating for Arconic Corp (NYSE: 
Via Benzinga
Aurinia's Voclosporin Shows favorable Risk/Benefit Profile Over 3 Years In Lupus Nephritis
Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) has posted topline results from the AURORA 2 continuation study evaluating the long-term safety and tolerability of... 
Via Benzinga
The Daily Biotech Pulse: Reata Plunges On Adcom Snub, AstraZeneca Antibody Cocktail Authorized For COVID-19 Prevention, NeuroSense IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus FDA Committee Votes Against Recommending Approval Of Kidney Disease Drug... 
Via Benzinga
Exposures COVID-19 Product Safety
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.